Stockscreener 앱 받기
0.3222
0.81%
0.0026
전일 마감가:
$0.3196
열려 있는:
$0.32
하루 거래량:
1.81M
Relative Volume:
1.01
시가총액:
$18.94M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.1244
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
-10.55%
1개월 성능:
-57.61%
6개월 성능:
-16.31%
1년 성능:
-33.69%
1일 변동 폭
$0.32
$0.3654
1주일 범위
$0.2926
$0.41
52주 변동 폭
$0.2601
$1.43
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3222 | 18.79M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-13 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
Big Money Moves: Should you buy the dip on BioAtla IncJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00 - Defense World
BioAtla (NASDAQ:BCAB) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
VIX Spike: Can BioAtla Inc deliver consistent dividendsJuly 2025 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioAtla Creates Super-Voting Share to Advance Reverse Split - The Globe and Mail
BioAtla stock initiated with Buy rating at Rodman & Renshaw - Investing.com
Why BioAtla Inc. stock remains resilientJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
BioAtla, Inc.Common Stock (NQ: BCAB - FinancialContent
Is BioAtla Inc. stock undervalued vs historical averages2025 Big Picture & Consistent Growth Stock Picks - ulpravda.ru
Is BioAtla Inc. stock attractive for hedge funds2025 Volatility Report & Daily Stock Trend Reports - Улправда
Is BioAtla Inc. stock dividend yield sustainable2025 Stock Rankings & Entry Point Confirmation Alerts - Улправда
What risks investors should watch in BioAtla Inc. stockEarnings Risk Report & Fast Entry Momentum Trade Alerts - Улправда
How BioAtla Inc. stock performs in rising dollar environmentMarket Volume Summary & Short-Term Trading Alerts - Улправда
How rising interest rates impact BioAtla Inc. stock2025 EndofYear Setup & Free Community Consensus Stock Picks - ulpravda.ru
Will BioAtla Inc. stock maintain momentum in 2025Volatility Index Analysis & Low Cost Portfolio Growth - ulpravda.ru
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
BioAtla’s Phase 3 Cancer Trial Is “AI-Backed”. Just Not in the Way You Think - AIM Media House
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Australia
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
Bioatla stock rises after $40 million SPV deal to advance cancer drug By Investing.com - Investing.com South Africa
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com India
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla Secures $5 Million Initial Funding for Phase 3 Trial of Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BioAtla adjourns special meeting, stockholders approve share issuance By Investing.com - Investing.com Australia
BioAtla Stockholders Approve Share Issuance, Delay Reverse Split - TipRanks
BioAtla adjourns special meeting, stockholders approve share issuance - Investing.com India
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):